Dr Matteo Lambertini speaks to ecancer about the present and future of precision oncology in breast cancer.


He begins by highlighting the current studies on PD-L1 expression in breast cancer; reviewing the IMpassion130 trial and the KEYNOTE-355 study design. 

He continues by discussing genomic test’s clinical utility in HR+/HER2- early-stage breast cancer, touching on the RxPONDER trial.

Dr Lambertini continues his presentation by looking towards the future, suggesting more attention to germline testing beyond BRCA and exploiting the use of liquid biopsy treatment implications. Improvement of types of imaging techniques, specifically molecular imaging is also needed.